EVER REACH GP: Xuchang Hengda plans to inject a registered capital of 24 million yuan into Xuchang City Hengrun
EVER REACH GP announced that Xuchang Hengda signed a capital injection agreement with Xuchang Municipal Investment. Xuchang Hengda will inject RMB 24 million, while Xuchang Municipal Investment will inject RMB 36 million. After the capital injection, the registered capital of Xuchang Hengrun will increase to RMB 160 million, and Xuchang Hengda's equity will decrease from 80% to 65%, while Xuchang Municipal Investment's equity will increase from 20% to 35%. The board of directors believes that the terms of the capital injection are fair and reasonable, in line with the overall interests of the company and its shareholders
According to the announcement from EVER REACH GP (03616), on October 30, 2025, (i) XuChang HengDa (a subsidiary of the company and one of the shareholders of XuChang City HengRun) and (ii) XuChang City Investment (another shareholder of XuChang City HengRun) entered into a capital injection agreement.
According to the capital injection agreement, (i) XuChang HengDa agrees to inject RMB 24 million into the registered capital of XuChang City HengRun; (ii) XuChang City Investment agrees to inject RMB 36 million into the registered capital of XuChang City HengRun; and (iii) upon completion of the capital injection, the registered capital of XuChang City HengRun will increase from RMB 100 million to RMB 160 million, and the equity of XuChang HengDa in XuChang City HengRun will be diluted from 80% to 65%, while the equity of XuChang City Investment in XuChang City HengRun will increase from 20% to 35%.
The directors (including independent non-executive directors) believe that although the capital injection is not conducted in the ordinary and normal course of business of the company, the terms of the capital injection are fair and reasonable, and the capital injection is made on normal commercial terms, which is in the overall interest of the company and its shareholders. No director has a significant interest in the capital injection, and no director is required to abstain from voting on the relevant board resolution to approve the capital injection
